Healthcare companies fell amid fears about an obesity-drug price war.
A rout in shares of Danish drug maker Novo Nordisk continued after it accused Hims & Hers of "illegal mass compounding." Earlier Thursday, Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan-copies made from the same active ingredient, semaglutide, as Novo Nordisk's treatment. Shares of Hims & Hers fell, too.
Eli Lilly shares fell sharply, reversing major gains in the wake of the Zepbound maker's quarterly earnings.
Cigna shares rose after the health insurer said growth at its pharmacy-benefit unit Evernorth offset weakness elsewhere.
Most health insurers continued their retreat, led by the largest insurer by enrollees UnitedHealth Group.
Cardinal Health shares surged after the drug wholesaler boosted its profit projection for the year on strong demand.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
02-05-26 1758ET
